News Release: July 22, 2025
Poly (Lactic-co-Glycolic Acid) (PLGA) Price, Production, Latest News and Developments in 2025
Poly (Lactic-co-Glycolic Acid) (PLGA) price trend and production News
Poly (Lactic-co-Glycolic Acid) (PLGA) Price Trend in Past Five Years and Factors Impacting Price Movements
Over the past five years, the Poly (Lactic-co-Glycolic Acid) (PLGA) price trend has experienced several fluctuations, primarily driven by shifts in raw material supply, regulatory policies, healthcare demand, and production capacity expansions. In 2020, the average Poly (Lactic-co-Glycolic Acid) (PLGA) price stood around $68,000/MT due to supply chain bottlenecks during the pandemic. This year witnessed limited production activities and sharp spikes in logistics costs, contributing to elevated prices.
In 2021, with improved global logistics and resumption of production, the average price dropped to $64,500/MT. The decline was also due to increased production outputs from manufacturers in Asia and Europe, who ramped up operations to cater to the delayed demand from the medical sector. However, demand from the pharmaceutical industry remained consistent, ensuring a floor for the Poly (Lactic-co-Glycolic Acid) (PLGA) price trend.
In 2022, the average PLGA price stabilized at around $62,800/MT. The market saw balanced dynamics between production and demand, with bioabsorbable sutures and drug delivery systems acting as key drivers of Poly (Lactic-co-Glycolic Acid) (PLGA) sales volume. Countries like China and South Korea increased their PLGA production capacity, easing some pressure on prices.
2023 saw a slight uptick in prices to an average of $65,000/MT, influenced by increased costs of lactic acid and glycolic acid—the two primary feedstocks. These feedstocks themselves experienced a rise in prices due to a surge in corn-based fermentation costs. A moderate rise in downstream demand, especially in advanced wound care and orthopedic applications, contributed to maintaining firm pricing throughout the year.
In 2024, the Poly (Lactic-co-Glycolic Acid) (PLGA) price climbed further, averaging $67,200/MT. Several factors contributed to this increase, including stricter environmental regulations in China affecting raw material availability, and enhanced demand in Western markets following new product launches by leading pharmaceutical companies. Research collaborations and clinical trials involving PLGA as a drug delivery vehicle also pushed demand upward.
Now in 2025, the estimated average Poly (Lactic-co-Glycolic Acid) (PLGA) price is hovering around $69,500/MT. This current pricing reflects a consistent rise backed by innovation, improved global health awareness, and the diversification of PLGA applications in medical implants and tissue engineering. The Poly (Lactic-co-Glycolic Acid) (PLGA) price news has been dominated by announcements of global capacity expansions and strategic tie-ups between biotechnology firms and PLGA manufacturers.
Cost of energy, labor dynamics in production countries, availability of fermentation substrates, and geopolitical trade factors remain the most impactful forces shaping the Poly (Lactic-co-Glycolic Acid) (PLGA) Price Trend. With more companies entering the specialty biopolymers market, competition is expected to keep prices in check while ensuring availability remains robust across medical sectors.
Poly (Lactic-co-Glycolic Acid) (PLGA) Price Trend Quarterly Update in $/MT (Estimated)
- Q1 2025: $68,800/MT
- Q2 2025: $69,300/MT
- Q3 2025 (ongoing): $69,500/MT
- Q4 2025 (projected): $70,200/MT
These figures reflect stable quarter-over-quarter growth, driven by an increase in global Poly (Lactic-co-Glycolic Acid) (PLGA) sales volume and rising input costs. The third quarter showed strong momentum in exports to North America and Europe, which supported higher prices.
Global Poly (Lactic-co-Glycolic Acid) (PLGA) Import-Export Business Overview
The global import-export landscape of Poly (Lactic-co-Glycolic Acid) (PLGA) continues to evolve rapidly in 2025, shaped by dynamic supply chains, shifting production hubs, and increasing demand for biocompatible materials. Several key trends are defining international trade of PLGA this year.
Asia-Pacific remains the dominant exporter of PLGA, particularly China, South Korea, and India. China, due to its well-integrated supply chain and significant investments in fermentation technologies, leads in low-cost high-volume PLGA production. Its export volume has risen steadily since 2023, with 2025 marking an estimated 12% year-on-year growth in outbound shipments. Indian manufacturers, though smaller in scale, have focused on high-purity medical-grade PLGA for European and Middle Eastern markets.
Europe, meanwhile, stands as a key importer, especially Germany, France, and the UK. Their domestic production capabilities are limited compared to demand generated by the pharmaceutical and biomedical sectors. In 2025, European import volumes of PLGA are projected to reach approximately 3,500 MT, marking a steady increase over the last two years. Strong collaborations between European biotech firms and Asian manufacturers have also led to a surge in custom formulation imports.
The United States remains both a significant importer and a niche exporter of PLGA. While domestic production supports local demand in the healthcare and research sectors, specific grades of PLGA used in advanced drug delivery systems are still sourced from Asia. Import volumes in the US reached nearly 4,200 MT in 2024 and are expected to touch 4,700 MT in 2025. Exports from the US are mainly directed toward Latin American countries and Canada, where demand for PLGA-based medical devices is increasing.
Japan has taken a strategic turn in 2025 by strengthening its domestic capabilities. With advanced R&D and high regulatory standards, Japan has focused on exporting ultra-high-purity PLGA to the US and Europe. Although export volumes are lower than China’s, the value per ton is significantly higher due to quality differentials. Japan’s export revenue from PLGA is projected to rise 15% this year.
Middle Eastern and African markets, while still emerging, are showing promise for future growth. Countries like the UAE and Saudi Arabia have begun importing PLGA for localized medical manufacturing, driven by national health reform agendas and medical tourism investments. Africa is still nascent in this regard, but ongoing discussions on local PLGA production plants in Egypt and South Africa are expected to reduce import dependency over the next five years.
Another factor driving international trade is the shift toward environmentally conscious sourcing. Countries in the European Union are increasingly seeking sustainable and traceable production practices in their PLGA imports. This has encouraged exporters to obtain quality and sustainability certifications, further shaping the import-export equation.
Trade logistics remain a pivotal factor in the Poly (Lactic-co-Glycolic Acid) (PLGA) Production and distribution chain. Rising freight charges and maritime challenges in certain routes have compelled companies to establish regional storage and distribution hubs. South Korea and Singapore, for example, have become critical transshipment points due to their strategic locations and developed infrastructure.
The Poly (Lactic-co-Glycolic Acid) (PLGA) sales volume through export markets is projected to cross 25,000 MT globally in 2025, with import volumes showing comparable figures, adjusted for intra-regional trade. This level of activity underscores the growing reliance of the global healthcare ecosystem on PLGA and its derivatives.
Overall, the global Poly (Lactic-co-Glycolic Acid) (PLGA) import-export business reflects a trend toward consolidation, specialization, and quality-led competition. With newer applications and rising global health standards, the international demand for PLGA continues to intensify, encouraging further production investments and trade alliances.
To explore detailed insights on production, sales, market share, and country-specific data, request the full report at:
https://datavagyanik.com/reports/poly-lactic-co-glycolic-acid-plga-market-size-production-sales-average-product-price-market-share-import-vs-export/
Poly (Lactic-co-Glycolic Acid) (PLGA) Production Trends by Geography
The global production landscape of Poly (Lactic-co-Glycolic Acid) (PLGA) is witnessing dynamic shifts as various regions adapt to rising demand, evolving regulatory frameworks, and expanding medical applications. In 2025, PLGA production continues to be led by countries with robust biopolymer infrastructure, established pharmaceutical industries, and increasing research investments.
Asia-Pacific
Asia-Pacific remains the largest producer of Poly (Lactic-co-Glycolic Acid) (PLGA), primarily driven by China, South Korea, and India. China holds a dominant position, thanks to a highly integrated chemical supply chain and cost-effective labor. With rapid industrial expansion and focused government support for biomedical research, China’s PLGA production capacity has increased by over 10% annually in recent years. Multiple domestic manufacturers are now supplying not only the local market but also exporting to North America and Europe. Chinese production facilities have also improved product purity standards to meet international requirements.
South Korea plays a crucial role with its strong biotech and pharmaceutical industries. The country focuses more on high-purity and medical-grade PLGA, used in drug delivery systems and implants. Korean manufacturers are known for high research investments, producing specialty grades of PLGA required for nanomedicine and tissue engineering.
India’s PLGA production sector has grown significantly in the last five years. While still developing in terms of large-scale output, Indian companies focus on supplying to domestic medical device manufacturers and smaller biotech companies. The Indian government’s Make-in-India initiative has helped attract investments into PLGA production facilities, particularly in southern and western states.
North America
The United States is a major hub for PLGA production, with advanced capabilities in biopolymers and pharmaceuticals. Leading American firms have developed proprietary PLGA formulations tailored for complex drug release applications. The US production environment is characterized by high compliance standards and innovation-driven output. Production is also increasingly aligned with sustainability goals, using renewable feedstocks where possible.
However, high production costs and raw material dependencies mean that the US continues to import a portion of its PLGA needs. Nonetheless, domestic production remains robust due to high-value demand from the medical device and pharmaceutical sectors.
Canada contributes moderately to North American PLGA production, with its biotech companies focusing on niche applications. Recent government grants have supported the establishment of pilot-scale facilities producing PLGA for R&D and clinical trial purposes.
Europe
Europe is both a consumer and producer of Poly (Lactic-co-Glycolic Acid) (PLGA), with Germany, Switzerland, and the Netherlands taking the lead in production. Germany is at the forefront with strong pharmaceutical and chemical industries. German firms specialize in producing pharmaceutical-grade PLGA using advanced fermentation and purification techniques. Europe’s focus on sustainable production practices also reflects in the regional PLGA supply chains, where green chemistry is gaining traction.
Switzerland, home to several pharmaceutical giants, also produces specialized PLGA formulations. The country focuses on high-purity, small-batch production tailored for injectable drug delivery and implantable systems.
The Netherlands and Belgium are emerging as secondary PLGA production hubs, leveraging their proximity to major European markets and port connectivity. EU funding programs have further enabled innovation in biopolymer production across the region.
Japan
Japan’s PLGA production is highly specialized. While not a high-volume producer like China or the US, Japan focuses on research-based production catering to advanced medical applications such as ophthalmic implants, cancer drug carriers, and gene therapy systems. With world-class R&D facilities and strict regulatory adherence, Japanese PLGA producers enjoy a reputation for ultra-high-quality grades suitable for critical applications.
Middle East and Latin America
The Middle East is beginning to invest in PLGA production, particularly the UAE and Saudi Arabia. These nations are developing medical manufacturing hubs and exploring localized biopolymer production to reduce dependence on imports. Current volumes are limited, but pilot projects and joint ventures with Asian partners are laying the groundwork for future production scaling.
In Latin America, Brazil and Mexico are making small strides in PLGA production. While local capacities remain low, there is growing interest in establishing biopolymer plants to support domestic healthcare manufacturing. These efforts are still in the early stages but reflect a positive long-term trend.
Africa
Africa remains largely dependent on imports for PLGA, though research initiatives in countries like South Africa and Egypt are exploring possibilities of local production. Most activity is still academic or experimental, with no large-scale commercial production yet. However, increasing demand for affordable medical materials could accelerate regional investments in coming years.
Overall, the global Poly (Lactic-co-Glycolic Acid) (PLGA) production ecosystem is becoming more diversified. While Asia-Pacific and North America dominate in volume and technological capabilities, other regions are gradually building up their production capacity in response to growing medical needs and strategic import substitution goals.
Poly (Lactic-co-Glycolic Acid) (PLGA) Market Segmentation
Segments:
- By Application
- By End-User
- By Product Type
- By Molecular Weight
- By Region
1. By Application
- Drug Delivery Systems
- Surgical Sutures
- Orthopedic Devices
- Wound Management
- Tissue Engineering
- Other Biomedical Applications
Drug delivery systems lead this segment, accounting for the highest Poly (Lactic-co-Glycolic Acid) (PLGA) sales volume globally. PLGA’s biodegradability and biocompatibility make it ideal for controlled drug release. It is extensively used in micro- and nanoparticles for delivering cancer drugs, hormones, and antibiotics. In 2025, with the rising incidence of chronic diseases, demand for PLGA in drug delivery continues to surge.
Surgical sutures represent another significant application. PLGA’s resorbable nature makes it perfect for internal stitching, where the suture naturally degrades post-surgery. Hospitals increasingly prefer PLGA-based sutures for minimizing infection risks and reducing the need for suture removal.
Orthopedic devices, including biodegradable screws and fixation pins, rely on high-strength PLGA formulations. These applications are seeing growth due to an aging population and more joint replacement surgeries globally.
Tissue engineering and wound care are emerging areas, with PLGA scaffolds used for skin regeneration, bone repair, and organ engineering. These segments, although smaller in volume, are growing rapidly due to increasing investments in regenerative medicine.
2. By End-User
- Pharmaceutical Companies
- Hospitals and Surgical Centers
- Research Institutes
- Biotechnology Firms
Pharmaceutical companies dominate PLGA consumption, using it in long-acting injectable drugs and implantable dosage forms. Biotech firms follow, particularly those focused on gene therapy, vaccines, and precision medicine. Hospitals primarily utilize PLGA in the form of sutures, staples, and scaffolds during surgery. Research institutes consume PLGA for R&D and clinical trial purposes, especially in drug formulation studies.
3. By Product Type
- Microspheres
- Nanoparticles
- Films and Membranes
- Fibers and Meshes
Microspheres are the most widely used product type, particularly in injectable drug delivery systems. Nanoparticles are gaining momentum for their enhanced bioavailability and targeting ability. Films and membranes are used in barrier devices, while fibers and meshes are common in tissue regeneration and wound management applications.
4. By Molecular Weight
- Low Molecular Weight
- Medium Molecular Weight
- High Molecular Weight
Low and medium molecular weight PLGA is preferred for drug delivery, offering controlled degradation rates. High molecular weight variants are used in orthopedic implants and load-bearing applications due to their enhanced mechanical strength. The selection often depends on the desired degradation profile and mechanical performance.
5. By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
North America remains the largest consumer of PLGA, with the US driving innovation in medical applications. Europe follows closely, with a strong focus on sustainable production and clinical use. Asia-Pacific leads in production and shows rapid consumption growth, especially in China and India. Latin America and the Middle East are emerging markets showing strong potential, driven by healthcare reforms and increased biomedical investments.